Xilio Therapeutics (XLO)Director bought ~$31K
James Samuel Shannon, Director at Xilio Therapeutics, bought ~$31K of Xilio Therapeutics shares.
- ~$31K
- Approx. value · 45K sh @ $0.686
- 45K
- Holds after · shares reported
- Traded
- Jun 16, 2025
- Filed
- Jun 18, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jun 16, 2025 · this disclosureInsiderDirector purchased ~$31K of XLO shares in the open market
What came next
- Jun 16, 2025InsiderCEO purchased ~$25K of XLO shares in the open market
- Jun 17, 2025InsiderDirector purchased ~$17K of XLO shares in the open market
- Oct 2, 2025Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On October 2, 2025, Xilio Therapeutics, Inc. (the “Company”) received approval from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of the Company’s common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market.”
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Xilio Therapeutics
OQRO holds no insider, Congress, fund or contract record for Xilio Therapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XLO page.
Other recent filings by James Samuel Shannon, Director
- SEC Form 4 at Xilio Therapeutics (XLO)Mar 30, 2026
- SEC Form 4 at Xilio Therapeutics (XLO)Jun 18, 2025
The full history of James Samuel Shannon, Director is on the profile page.
How this filing works
Other disclosures at Xilio Therapeutics
- SEC Form 4Mar 30, 2026
- SEC Form 4Jan 5, 2026
- SEC Form 4Jan 5, 2026
- SEC Form 4Jun 18, 2025
- SEC Form 4Jun 18, 2025
- SEC Form 4Jan 3, 2025
Everything OQRO holds on this company is on its XLO page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data